MorningSunNCT05207670
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies
At risk: Primary completion moved at least 2 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 46 versions: 38 with changes below, 8 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 54 words
- Primary completion pushed from Jul 31, 2027 to Oct 1, 2027
- Study completion pushed from Jul 31, 2027 to Oct 29, 2027
- Site details revised at 4 of 39 sites
- Notable Primary and study completion moved earlier from Jul 31, 2028 to Jul 31, 2027v44
- Minor Study sites revised (39)v42
- Minor Site details revised at 1 of 39 sitesv40
- Minor Study sites: 41 to 39v39
Show 32 earlier versionsHide 32 earlier versions
- Minor Enrollment target: estimated 345 to confirmed 320v38
- Minor Trial status: Recruiting to Active, Not Recruiting
- Study sites: 58 to 41
- Minor Site details revised at 3 of 58 sitesv36
- Minor Site details revised at 2 of 58 sitesv34
- Minor Study sites revised (58)v33
- Minor Study sites revised (58)v32
- Minor Study sites: 57 to 58v31
- Minor Study sites revised (57)v30
- Minor Study sites revised (57)v29
- Minor Site details revised at 3 of 57 sitesv26
- Minor Study sites: 56 to 57v25
- Minor Study sites: 54 to 56v23
- Minor Study sites: 53 to 54v22
- Minor Site details revised at 1 of 53 sitesv21
- Minor Study sites: 48 to 53v19
- Minor Study sites: 46 to 48v18
- Minor Study sites: 44 to 46v17
Notable Primary and study completion dates: Dec 17, 2026 to Jul 31, 2028v16 Show 4 more changesShow less
- Eligibility criteria expanded, about 131 words
- Enrollment target: 275 to 345
- Study sites: 39 to 44
- Secondary endpoints: 9 to 10
- Minor Study sites: 37 to 39v15
- Minor Site details revised at 1 of 37 sitesv14
- Minor Study sites: 27 to 37v13
- Minor Study sites: 25 to 27v12
- Minor Study sites: 22 to 25v11
- Minor Study sites: 20 to 22v10
- Minor Study sites: 19 to 20v9
- Notable Eligibility criteria expanded, about 1 word
- Study sites: 18 to 19
- Minor Study sites: 14 to 18v7
- Notable Eligibility criteria expanded, about 17 words
- Study sites: 10 to 14
- Minor Study sites: 5 to 10v5
- Minor Study sites: 2 to 5v4
- Minor Start date changed from estimate of Feb 15, 2022 to Feb 1, 2022v3
- Minor Study sites: 1 to 2
- Start date: Jan 21, 2022 to Feb 15, 2022
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (10)
Show 5 moreShow less
Arms and interventions
Participants with high tumor burden with untreated follicular lymphoma (FL) will receive SC mosunetuzumab monotherapy for up to 17 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first. Participants that achieve complete or partial metabolic response will have the option of receiving maintenance therapy with mosunetuzumab every 8 weeks for 1 year.
Elderly participants with untreated diffuse large B-cell lymphoma (DLBCL) will receive SC mosunetuzumab monotherapy for up to 17 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.
Participants with untreated marginal zone lymphoma (MZL) will receive SC mosunetuzumab monotherapy for up to 17 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.
Participants with relapsed or refractory (R/R) mantle cell lymphoma (MCL) will receive SC mosunetuzumab monotherapy for up to 34 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.
Participants with R/R Richter's transformation (RT), or R/R transformed follicular lymphoma (tFL) will receive SC mosunetuzumab monotherapy for up to 34 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.
Drugs: Mosunetuzumab (Cohorts A-C), Mosunetuzumab (Cohorts D-E), Tocilizumab
Sites
39 sites in 1 country